Medicare Congress: Agenda: Day 3

Pre-Conference/
Day One

Day Two

Day Three

Agenda: Day 3 Friday, February 27, 2004 Held at Hyatt Regency on Capitol Hill
8:00 a.m.	CONCURRENT SESSIONS I
	1.01 The Implications of the New Medicare Prescription Drug Legislation to Pharmaceutical Manufacturers G. Lawrence Atkins, Ph.D. Senior Director, Public Policy and Reimbursement Schering-Plough Corporation Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint) Ian Spatz Vice President, Public Policy Merck & Co., Inc. Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint)
	1.02 Why the Liberal Democrats Opposed the New Medicare Prescription Drug Legislation Marilyn Moon, Ph.D. Vice President and Director of Health American Institutes for Research Former Urban Institute Senior Fellow and Trustee of the Medicare and Social Security Trust Funds Washington, DC
	1.03 The New Medicare Drug Benefit: Raising the Bar on Operational and Compliance Standards in the Pharmaceutical Industry Anthony Farino Partner-in-Charge, Global Pharmaceutical & Health Sciences Group PricewaterhouseCoopers LLP Chicago, IL Jonathon Kellerman Sr. Manager PricewaterhouseCoopers Global Pharmaceutical & Health Sciences Group PricewaterhouseCoopers LLP Philadelphia, PA Presentation Material (Acrobat) Presentation Material (Powerpoint) Timothy Nugent Sr. Manager PricewaterhouseCoopers Global Pharmaceutical & Health Sciences Group PricewaterhouseCoopers LLP Florham Park, NJ
	1.04 The Role of Actuarial Equivalence under MRxIMA John Bertko, FSA Vice President and Chief Actuary, Humana, Inc. Louisville, KY Presentation Material (Acrobat) Presentation Material (Powerpoint) Margaret Wear, ASA, MAAA, FCA Vice President, Rx Actuary PacifiCare Health Systems Santa Ana, CA
	1.05 Background to Prescription Drug Discount Cards, the 2002 Regulations and Following Litigation and the New Medicare-Endorsed Prescription Drug Discount Card Program: How it Will Work and Who Will Participate Kirby Bessant Vice President, Consumer Programs AdvancePCS Scottsdale, AZ Presentation Material (Acrobat) Presentation Material (Powerpoint) Kristina E. Lunner Director, Federal Government Affairs American Pharmacists Association Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint) Timothy P. Trysla, Esq. Policy Advisor to the CMS Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services Washington, DC John Richardson, MPP Director, Medicare The Health Strategies Consultancy LLC Washington, DC (Moderator) Presentation Material (Acrobat) Presentation Material (Powerpoint)
	1.06 The Reimportation Debate John E. Calfee, Ph.D. Research Scholar, American Enterprise Institute Author, Prices, Markets, and the Pharmaceutical Revolution Washington, DC Handout Material (Acrobat) Tom McGinnis Director of Pharmacy Affairs Food and Drug Administration Rockville, MD Stephen W. Schondelmeyer, PharmD, Ph.D. Professor and Head, Department of Pharmaceutical Care and Health Systems Century Mortar Club Endowed Chair in Pharmaceutical Management and Economics University of Minnesota Minneapolis, MN Susan C. Winckler, R.Ph., JD Vice President, Policy & Communications and Staff Counsel American Pharmacists Association Washington, DC Larry Levitt Vice President, Kaiser Family Foundation Editor-in-Chief, KaiserNetwork.org Washington, DC (Moderator)
	1.07 Prosecuting Violations under the New Medicare Prescription Drug Legislation Jack Hartwig, Esq. Leader, Health Care and Life Sciences Investigations Team Deloitte & Touche Former Deputy Inspector General for Investigations Department of Health and Human Services Philadelphia, PA Presentation Material (Acrobat) Presentation Material (Microsoft Word) Handout Material (Acrobat) Handout Material (Microsoft Word) James Sheehan, Esq. Associate United States Attorney U.S. Attorney's Office for the Eastern District of Pennsylvania Philadelphia, PA Presentation Material (Acrobat) Presentation Material (Powerpoint)
9:00 a.m.	Transition Break
9:15 a.m.	CONCURRENT SESSIONS II
	2.01 Prescription for Disaster? Market Triumphs and Travesties from the Managed Care Drug Wars J.D. Kleinke Medical Economist Author and President of Health Strategies Network, Inc., a Health Care Business and Information Technology Strategy Company Based in Portland, OR
	2.02 Helping Seniors Make Smart Prescription Drug Decisions under the New Medicare Prescription Drug Legislation Donald W. Kemper, MPH Chairman and Chief Executive Officer, Healthwise, Inc. Founder, Center for Information Therapy Boise, ID Presentation Material (Acrobat) Presentation Material (Powerpoint) Hal Prink, FHMA Medicare Patient Advocate Senior's Voice for Healthcare Rights Denver, CO Presentation Material (Acrobat) Presentation Material (Powerpoint) Handout Material (Acrobat) Handout Material (Microsoft Word) Handout Material (Acrobat) Handout Material (Microsoft Word)
	2.03 The Impact of the New Medicare Prescription Drug Legislation on Pharmaceutical R&D Investments and Pricing Bert Spilker, Ph.D., MD Adjunct Professor of Medicine UNC Medical School, Chapel Hill Clinical Professor of Pharmacy, UNC President, Bert Spilker & Associates Bethesda, MD William Testerman Principal, Ernst & Young LLP Former Senior Health Policy Advisor Senator Bill Frist, MD Washington, DC
	2.04 The Implications of the New Medicare Prescription Drug Legislation on Pharmaceutical Revenue Jack Rodgers, Ph.D. Director, Health Policy Economics Group PricewaterhouseCoopers LLP Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint) Ian Spatz Vice President, Public Policy Merck & Co., Inc. Washington, DC
	2.05 HIPAA Pharmacy Transactions and Code Sets: Will They Support the Implementation of the New Pharmaceutical Benefit in 2006? Steven S. Lazarus, Ph.D., FHIMSS President, Boundary Information Group Immediate Past Chair, Workgroup for Electronic Data Interchange (WEDI) Denver, CO Presentation Material (Acrobat) Presentation Material (Powerpoint) Mary Ryan Vice President, Corporate Regulatory Group Medco Health Solutions, Inc. Franklin Lakes, NJ
	2.06 The New Medicare Prescription Drug Legislation's Implications for the Pharmaceutical Sector's Financial Markets David Moskowitz, MBA, R.Ph. Senior Vice President and Healthcare Senior Analyst Friedman, Billings, Ramsey Group, Inc. Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint) Richard T. Evans Senior Research Analyst of Global Pharmaceuticals Sanford C. Bernstein & Co. New York, NY Presentation Material (Acrobat) Presentation Material (Powerpoint) Lambert van der Walde Capital Markets Advisor Centers for Medicare & Medicaid Services Department of Health and Human Services Washington, DC
	2.07 OPEN
10:15 a.m.	Break
10:45 a.m.	CONCURRENT SESSIONS III
	3.01 The ePrescribing Provisions of the New Medicare Law and How They will Change the Pharmaceutical Supply Chain Louis E. Hyman Executive Vice President, CTO HealthRamp, Inc. New York, NY Presentation Material (Acrobat) Presentation Material (Powerpoint) Dan Mendelson, MPP President and Founder, The Health Strategies Consultancy LLC Former Associate Director for Health Office of Management and Budget Washington, DC
	3.02 Far Reaching and Immediate Impacts of the New Medicare Prescription Legislation on MCOs and PBMs Mark W. Owen Vice President and General Manager Medica, Center for Healthy Aging Minnetonka, MN Presentation Material (Acrobat) Presentation Material (Powerpoint) Jack Scott Senior Manager, Deloitte & Touche LLP Pittsburgh, PA Leslie J. Weitzman Principal, Deloitte & Touche LLP Chicago, IL Presentation Material (Acrobat) Presentation Material (Powerpoint)
	3.03 Will the New Legislation Improve the Market for Prescription Drugs: Assessing the Impact of the Formulary Provisions and the Amendments to the Medicaid Best Price Law? How to Get from Existing Legislation to a more Coherent Drug Benefit in an Affordable Manner Anthony A. Barrueta, Esq. Senior Counsel, Government Relations Kaiser Foundation Health Plan, Inc. Oakland, CA Presentation Material (Acrobat) Presentation Material (Powerpoint)
	3.04 The Implications of the New Medicare Prescription Drug Legislation to MediGap Insurers Marianne Miller Director of Federal Regulatory Affairs and Policy Development AAHP-HIAA Washington, DC Presentation Material (Acrobat) Presentation Material (Microsoft Word) Larry A. Oday, Esq. Partner, Vinson & Elkins LLP Former HCFA Director of Congressional Affairs Washington, DC Handout Material (Acrobat) Handout Material (Microsoft Word) William G. Schiffbauer, Esq. Founding Partner, Schiffbauer Law Office Washington, DC Handout Material (Acrobat) Handout Material (Microsoft Word) Handout Material (Acrobat) Handout Material (Microsoft Word)
	3.05 Will Employers Continue to Offer Prescription Drug Coverage Following Implementation of the New Medicare Prescription Drug Program? Derek Guyton, FSA Principal, Mercer Human Resource Consulting Chicago, IL Lisa Zeitel, MPH Principal and National Leader Managed Pharmacy Group Mercer Human Resource Consulting Norwalk, CT Presentation Material (Acrobat) Presentation Material (Powerpoint)
	3.06 HIPAA and Patient Privacy Issues Raised by the New Medicare Prescription Drug Program Alan S. Goldberg, JD, LLM Partner, Goulston & Storrs Adjunct Professor, University of Maryland School of Law Moderator, AHLA HIT Listserve Washington, DC Presentation Material (Acrobat) Linda A. Malek, Esq. Partner, Moses & Singer LLP New York, NY Presentation Material (Acrobat) Presentation Material (Powerpoint)
	3.07 The New Medicare Prescription Drug Legislation: Implications for the States Bernie Horn Policy Director Center for Policy Alternatives Washington, DC
11:45 a.m.	Networking Luncheon
12:45 p.m.	CONCURRENT SESSIONS IV
	4.01 Will PBMs Participate in the New Medicare Prescription Drug Program, and if so, How? Michael H. Deskin President, Pharmacy Benefit Management Institute, Inc. Tempe, AZ Presentation Material (Acrobat) Presentation Material (Powerpoint) Brian D. Glassman Director, Market Planning and Development Prime Therapeutics Eagan, MN Presentation Material (Acrobat) Presentation Material (Powerpoint) Terry Latanich Former Senior Vice President Government Affairs, MedcoHealth Former Chair, Government Healthcare Programs Committee Pharmaceutical Care Management Association Franklin Lakes, NJ Presentation Material (Acrobat) Presentation Material (Powerpoint)
	4.02 The Implications of the Information Technology Provisions on the New Medicare Legislation to the Pharmaceutical Sector Janet M. Marchibroda Chief Executive Officer, eHealth Initiative Executive Director, Foundation for eHealth Initiative and Markle Foundation's Connecting for Health Washington, DC
	4.03 The Implications of Medicare Drug Benefits for PBMs and Retiree Health Benefit Plans Bill Rosenberg Director, Health Care Practice PricewaterhouseCoopers LLP New York, NY Presentation Material (Acrobat) Presentation Material (Powerpoint)
	4.04 Product Development Strategies for Medicare+Choice and Medicare Advantage Tom L. Anderson Principal, Gorman Health Group, LLC Former Senior Vice President of Strategies and Planning United Healthcare Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint) John K. Gorman President and Chief Executive Officer Gorman Health Group, LLC Former Press Secretary and Staff Director U.S. Representative John Conyers, Jr. (D-MI) Former Assistant to the Director, HCFA's Office of Managed Care Washington, DC
	4.05 The Implications of the New Medicare Prescription Drug Legislation for Pharmaceutical Market Structure and Profitability Sander A. Flaum Managing Partner, Flaum Partners, Inc. Chairman, Fordham Leadership Forum Fordham Graduate School of Business New York, NY Presentation Material (Acrobat)
	4.06 How the New Medicare Prescription Drug Legislation Will Bring the Pharmaceutical Industry under the Microscope and Authority of the Regulators at CMS, and Enforcement Officials at OIG and DOJ Christopher Ideker Partner, Ernst & Young Former Compliance Officer, Per-Se Technologies Atlanta, GA Presentation Material (Acrobat) Presentation Material (Powerpoint) Richard P. Kusserow President, Strategic Management Systems, Inc. Former Inspector General, Department of Health & Human Services Washington, DC Presentation Material (Acrobat) Presentation Material (Microsoft Word)
	4.07 "Wither Thou Goest...." The Impact of Part B Reimbursement Reform on Private Insurance Payment: The Future of AWP-based Reimbursement Robert Homchick, Esq. Partner and Chair, Health Law Group Davis Wright Tremaine Seattle, WA Presentation Material (Acrobat) Presentation Material (Powerpoint) Howard Tag, Esq. President, Tag & Associates, PC Senior Counselor on Healthcare Payment and Reimbursement, Edelman Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint)
1:45 p.m.	Transition Break
2:00 p.m.	CONCURRENT SESSIONS V
	5.01 Scoring the Costs of the New Medicare Pharmaceutical Benefit Philip Ellis, Ph.D. Principal Analyst, Health and Human Services Congressional Budget Office Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint) Steve Lieberman Assistant Director for Health & Human Resources Congressional Budget Office Washington, DC
	5.02 The Implications of the New Medicare Prescription Drug Legislation to Pharmaceutical Sector Regulatory Compliance Programs John Bentivoglio, Esq. Partner, Arnold and Porter Former Special Counsel for Healthcare Fraud Chief Privacy Officer, United States Department of Justice Washington, DC Brenton L. Saunders, JD, MBA Senior Vice President, Global Compliance and Business Practices Schering-Plough Corporation Past President, Health Care Compliance Association Founder and Chair-elect, International Association of Privacy Officers Kenilworth, NJ Scott Willoughby, JD, R.Ph. Senior Manager, Ernst & Young Former Associate General Counsel Pharmaceutical Research and Manufacturers of America (PhRMA) Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint)
	5.03 Improving Access to Generic Pharmaceuticals: What the New Medicare Prescription Drug Coverage Legislation Does (and Does Not) Do Charles Raubicheck Partner, Frommer Lawrence & Haug LLP New York, NY
	5.04 The New Medicare Prescription Drug Legislation: What Institutional Investors and Research Analysts Need to Know R. Alexander Vachon, III, Ph.D. Hamilton PPB Former Chief Social Security Analyst Senate Finance Committee Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint)
	5.05 Medicare Drug Price Reporting and Reimbursement Paul E. Kalb, MD, JD Partner, Sidley Austin Brown & Wood Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint) David Rogers Partner, Health Care & Life Sciences Regulatory Consulting Group Deloitte & Touche LLP Boston, MA Presentation Material (Acrobat) Presentation Material (Powerpoint)
	5.06 Drug Reimportation: Learning from Experience in Europe Jim Furniss Director, Pricing and Reimbursement Bridgehead Technologies Member, European Commission's Pharmaceutical Pricing Transparency Committee Leicestershire, UK Presentation Material (Acrobat) Presentation Material (Powerpoint)
3:00 p.m.	Transition Break
3:15 p.m.	CONCURRENT SESSIONS VI
	6.01 Will the Medicare Competition Demonstrations Scheduled for 2010 Ever Take Place? Joseph Antos, Ph.D., MA Wilson H. Taylor Scholar in Health Care and Retirement Policy American Enterprise Institute Former Assistant Director for Health and Human Resources Congressional Budget Office Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint) Len Nichols, Ph.D. Vice President, Center for Studying Health System Change Former Senior Advisor for Health Policy Office of Management and Budget Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint)
	6.02 Exploring the Interaction between Medicare Part B and Medicare Part D Jennifer Breuer, Esq. Partner, Gardner Carton & Douglas, LLP Chicago, IL Presentation Material (Acrobat) Presentation Material (Powerpoint) Handout Material (Acrobat) Handout Material (Powerpoint) Holley Lutz, Esq. Partner, Gardner Carton & Douglas, LLP Washington, DC Chris Mancill, MA, CCP Director, Health Policy and Payer Relations PAREXEL International Corporation Editor-in-Chief, Medicare Drug Monitor Washington, DC
	6.03 The Financial Risks and Subsidized Rewards for Providing Retiree Rx Coverage: A Plan Sponsor's Guide to Plan Design Issues in Light of the Medicare Drug Improvement and Modernization Act of 2003 Mark Mathis, JD, LLM Associate, Baker Botts LLP Dallas, TX Presentation Material (Acrobat) Presentation Material (Powerpoint) Bruce D. Pingree, Esq. Partner, Baker Botts LLP Dallas, TX Presentation Material (Acrobat) Presentation Material (Microsoft Word)
	6.04 Implications of a Medicare Prescription Drug Benefit and Discount Card for Residents of Long-Term Care Facilities Mary Jo Carden, R.Ph., Esq. Principal, Dumbarton Group & Associates, LLC Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint) Leigh Davitian, Esq. Principal, Dumbarton Group & Associates, LLC Washington, DC
	6.05 New Opportunities for Drugs under Old Medicare: Changes to Inpatient New Technology Pass-Throughs and 'Incident to' Coverage Chris L. Keough, Esq. Partner, Vinson & Elkins, LLP Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint) Andrew Ruskin, Esq. Associate, Vinson & Elkins, LLP Washington, DC Presentation Material (Acrobat) Presentation Material (Powerpoint)
4:15 p.m.	Adjournment